Celadon Pharmaceuticals (CEL) Competitors GBX 13.40 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock CEL vs. CNSL, OTT, BCE, FOX, CZN, CHT, DVW, BRCI, NPT, and RCIShould you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Fox Marble (FOX), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry. Celadon Pharmaceuticals vs. Its Competitors Cambridge Nutritional Sciences Oxford Technology 3 Venture Capital Trust Beacon Energy Fox Marble Curzon Energy 290005 (CHT.L) 5008 (DVW.L) BlackRock Comms Income Inv Tst NetPlay TV RapidCloud International Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk. Is CEL or CNSL more profitable? Cambridge Nutritional Sciences has a net margin of -3.36% compared to Celadon Pharmaceuticals' net margin of -4,024.62%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celadon Pharmaceuticals-4,024.62% -187.26% -34.40% Cambridge Nutritional Sciences -3.36%-3.34%-2.36% Do insiders & institutionals hold more shares of CEL or CNSL? 10.7% of Celadon Pharmaceuticals shares are held by institutional investors. Comparatively, 10.2% of Cambridge Nutritional Sciences shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Cambridge Nutritional Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, CEL or CNSL? Celadon Pharmaceuticals has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 3.89, indicating that its share price is 289% more volatile than the S&P 500. Which has preferable earnings and valuation, CEL or CNSL? Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeladon Pharmaceuticals£123.38K66.61-£4.97M-£7.98-1.68Cambridge Nutritional Sciences£9.77M0.92-£3.03MN/AN/A Does the media prefer CEL or CNSL? In the previous week, Celadon Pharmaceuticals had 1 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 1 mentions for Celadon Pharmaceuticals and 0 mentions for Cambridge Nutritional Sciences. Celadon Pharmaceuticals' average media sentiment score of 0.41 beat Cambridge Nutritional Sciences' score of 0.00 indicating that Celadon Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Celadon Pharmaceuticals Neutral Cambridge Nutritional Sciences Neutral SummaryCeladon Pharmaceuticals and Cambridge Nutritional Sciences tied by winning 6 of the 12 factors compared between the two stocks. Get Celadon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CEL vs. The Competition Export to ExcelMetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£8.22M£2.13B£5.50B£2.96BDividend YieldN/A2.92%5.39%5.02%P/E Ratio-1.684.1326.57148.37Price / Sales66.61541.40415.46254,913.50Price / Cash3.0510.3536.1327.97Price / Book3.5312.348.065.30Net Income-£4.97M£21.15B£3.15B£5.90B7 Day Performance-2.83%2.41%1.72%0.21%1 Month Performance-9.21%5.14%3.92%4.78%1 Year Performance-81.74%2.65%35.02%80.43% Celadon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCeladon PharmaceuticalsN/AGBX 13.40flatN/A-81.9%£8.22M£123.38K-1.682,780News CoverageGap DownCNSLCambridge Nutritional SciencesN/AGBX 3.20-11.1%N/A+11.4%£7.61M£9.77M-362.103,200Gap UpOTTOxford Technology 3 Venture Capital TrustN/AN/AN/AN/A£2.13M-£85K-12.59203Gap DownBCEBeacon EnergyN/AGBX 0+33.3%N/AN/A£740KN/A-0.3544,600FOXFox MarbleN/AGBX 0.04-7.9%N/A-97.2%£146K£722.06K-135.0010,600Gap DownCZNCurzon EnergyN/AN/AN/AN/A£34KN/A-3.4014,700Gap DownCHT290005 (CHT.L)N/AN/AN/AN/A£0.00N/A0.0020,300News CoverageDVW5008 (DVW.L)N/AN/AN/AN/A£0.00N/A0.00N/AGap UpBRCIBlackRock Comms Income Inv TstN/AN/AN/AN/A£0.00N/A0.00N/AHigh Trading VolumeNPTNetPlay TVN/AN/AN/AN/A£0.00N/A0.00147,000RCIRapidCloud InternationalN/AN/AN/AN/A£0.00N/A0.0023,000 Related Companies and Tools Related Companies Cambridge Nutritional Sciences Competitors Oxford Technology 3 Venture Capital Trust Competitors Beacon Energy Competitors Fox Marble Competitors Curzon Energy Competitors 290005 (CHT.L) Competitors 5008 (DVW.L) Competitors BlackRock Comms Income Inv Tst Competitors NetPlay TV Competitors RapidCloud International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:CEL) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
